Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.

Retina (Philadelphia, Pa.) - 1 Jan 2012

Orlin Anton, Hadley Dexter, Chang Woohyok, Ho Allen C, Brown Gary, Kaiser Richard S, Regillo Carl D, Godshalk Ashlee N, Lier Audun, Kaderli Brian, Stambolian Dwight

Abstract excerpt

PURPOSE: To investigate whether there is an association between known age-related macular degeneration genetic risk variants in the CFH, ARMS2, and HTRA1 genes and response to anti-vascular endothelial growth factor (VEGF) (ranibizumab or bevacizumab) treatment for wet age-related macular degeneration. METHODS: A retrospective review of 150 patients with documented wet age-related macular degeneration based on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Complement Factor H

Share to Drug Administration Schedule

Share to High-Temperature Requirement A Serine Peptidase 1

Share to Macular Degeneration

Share to Visual Acuity

Source

Open in PubMed Open full text

Identifiers

PMID: 21878851
DOI: 10.1097/IAE.0b013e31822a2c7c
PMCID: PMC7440363

Genes

ARMS2
CFH
HTRA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between high-risk disease loci and response to anti-vascular endothelial growth factor treatment for wet age-related macular degeneration.PMID 21878851Read ↗

Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetics in neovascular age-related macular degeneration susceptibility and treatment response to anti-VEGF intravitreal injection: A case series study.Semantic proximity Read ↗

Genetic biomarkers in the VEGF pathway predicting response to anti-VEGF therapy in age-related macular degenerationSemantic proximity Read ↗

Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration.Semantic proximity Read ↗

Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration.Semantic proximity Read ↗

Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.Semantic proximity Read ↗

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).Semantic proximity Read ↗

VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).Semantic proximity Read ↗

Genetic associations of anti-vascular endothelial growth factor therapy response in age-related macular degeneration: a systematic review and meta-analysis.Semantic proximity Read ↗

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degenerationSemantic proximity Read ↗

CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.